Gathering the record
Relay is organizing the evidence and source boundaries.
GLP-1/GIP/glucagon triple-agonist peptide
An experimental drug being studied for weight loss, diabetes, and fatty-liver disease.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Phase 2 studies are registered and a Phase 3 obesity program is active; Relay does not treat sponsor toplines as equivalent to a complete peer-reviewed pivotal publication.
Regulatory and identity status determine how the evidence should be interpreted.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Risks & unknowns
Pivotal safety is not yet established; gastrointestinal, gallbladder, pancreatic, heart-rate, glucose, lean-mass, and glucagon-pathway questions require complete trial reporting.
Registered study — no resultsReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational; active Phase 2 and Phase 3 programs, no FDA approval. Confirmed Phase 3 efficacy, durability, cardiovascular outcomes, lean-mass effects, uncommon harms, and regulatory review.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
A planned schedule from a study registry or protocol. Registration alone does not establish approval, completed results, or benefit.
NCT07177469 specifies four weekly subcutaneous schedules for adults with overweight or obesity. These are registered plans, not evidence of results.
| Study weeks | 2 mg target | 4 mg · 0.5 mg start | 4 mg · 1 mg start | 6 mg target |
|---|---|---|---|---|
| Weeks 1–4 · start | 0.5 mg | 0.5 mg | 1 mg | 1 mg |
| Weeks 5–8 | 1 mg | 1 mg | 2 mg | 2 mg |
| Weeks 9–12 | 2 mg | 2 mg | 4 mg | 4 mg |
| Weeks 13–24 | 2 mg | 4 mg | 4 mg | 6 mg |
Each column is a separate registered arm. A trial registration does not validate a self-treatment schedule, demonstrate efficacy, or establish powder-vial preparation.
ClinicalTrials.gov · NCT07177469 Arms and interventions · four UBT251 dose groupsThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Official trial registries describe Phase 2 and Phase 3 studies in adults with obesity or overweight, but Relay's verified record does not yet contain posted pivotal outcomes.
Population: Adults with overweight or obesity
Design: Registered interventional trial
Mechanisms
Registered programs span obesity, type 2 diabetes, MASH, kidney disease, and drug-interaction questions. Sponsor toplines and registry entries must remain separate from peer-reviewed outcome reports.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Active human development with registry and sponsor-reported evidence; pivotal peer-reviewed outcome evidence remains incomplete.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confirmed Phase 3 efficacy, durability, cardiovascular outcomes, lean-mass effects, uncommon harms, and regulatory review.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A registered study describes planned research and cannot establish efficacy or safety. No numerical administration pattern, approved product, or generic-vial preparation claim is published here without a complete primary record. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with overweight or obesity
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with MASH
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Registered interventional trial
Adults with type 2 diabetes
Endpoints were not fully described in the current record.
No plain-English finding recorded.
Study administration: Not stated in the current record.
Limitations: Registered study; no posted results were represented at the evidence cutoff.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
NCT07177469
NCT07648225
NCT07145151
NCT07668388